{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:49:45Z","timestamp":1790394585961,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","award":["140604"],"award-info":[{"award-number":["140604"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Familjen Erling-Perssons Stiftelse","doi-asserted-by":"publisher","award":["AT"],"award-info":[{"award-number":["AT"]}],"id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P30482"],"award-info":[{"award-number":["P30482"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009240","name":"Sveriges Kommuner och Landsting","doi-asserted-by":"publisher","award":["ALFGBG-426741\/717321"],"award-info":[{"award-number":["ALFGBG-426741\/717321"]}],"id":[{"id":"10.13039\/501100009240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"British Microcirculation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010109","name":"Medizinische Universit\u00e4t Graz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001610","name":"Falk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2013-2569\/2016-01125"],"award-info":[{"award-number":["2013-2569\/2016-01125"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jhep.2019.06.011","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T23:34:44Z","timestamp":1561592084000},"page":"986-991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Obeticholic acid may increase the risk of gallstone formation in susceptible patients"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-2327","authenticated-orcid":false,"given":"Samer","family":"Al-Dury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-106X","authenticated-orcid":false,"given":"Katrin","family":"Panzitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Thorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"St\u00e5hlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"B\u00e4ckhed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"F\u00e4ndriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-3085","authenticated-orcid":false,"given":"Hanns-Ulrich","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.06.011_b0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2019.06.011_b0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstrom","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2019.06.011_b0015","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2018.06.038","article-title":"An FXR agonist reduces bile acid synthesis independently of increases in FGF19 in healthy volunteers","volume":"155","author":"Al-Khaifi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.06.011_b0020","doi-asserted-by":"crossref","first-page":"G940","DOI":"10.1152\/ajpgi.00398.2012","article-title":"Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids","volume":"304","author":"Zhang","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2019.06.011_b0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.06.011_b0030","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2019.06.011_b0035","first-page":"GS-06","article-title":"Positive results from REGENERATE: A phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH","volume":"70","author":"Zounossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.06.011_b0040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.06.011_b0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmet.2015.07.009","article-title":"Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation","volume":"22","author":"Tremaroli","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2019.06.011_b0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0022-2275(20)40677-7","article-title":"Critical tables for calculating the cholesterol saturation of native bile","volume":"19","author":"Carey","year":"1978","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2019.06.011_b0055","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-2275(20)38331-0","article-title":"Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions","volume":"30","author":"Heuman","year":"1989","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2019.06.011_b0060","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","author":"Al-Dury","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2019.06.011_b0065","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nm1138","article-title":"Prevention of cholesterol gallstone disease by FXR agonists in a mouse model","volume":"10","author":"Moschetta","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2019.06.011_b0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nm1501","article-title":"Identification of a hormonal basis for gallbladder filling","volume":"12","author":"Choi","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2019.06.011_b0075","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0022-2275(20)37603-3","volume":"37","author":"Wang","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2019.06.011_b0080","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.22771","article-title":"High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis","volume":"49","author":"Schaap","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.06.011_b0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2796.2007.01783.x","article-title":"Gallstone disease","volume":"261","author":"Marschall","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.jhep.2019.06.011_b0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.24702","article-title":"The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract","volume":"55","author":"Zweers","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.06.011_b0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.physiol.70.113006.100441","article-title":"Regulation of airway mucin gene expression","volume":"70","author":"Thai","year":"2008","journal-title":"Annu Rev Physiol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819303836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:54:24Z","timestamp":1777510464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819303836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0168827819303836"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.06.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obeticholic acid may increase the risk of gallstone formation in susceptible patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}